Role of magnesium sulphate as a neuroprotective agent on neonatal outcome in preterm deliveries

Authors

  • Neena Gupta Department of Obstetrics and Gynecology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India
  • Uruj Jahan Department of Obstetrics and Gynecology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India
  • Swadha Seep Department of Obstetrics and Gynecology, Rama Medical College, Kanpur, Uttar Pradesh, India
  • C. P. Singh Department of Pediatrics, Regency Hospital, Kanpur, Uttar Pradesh, India
  • Savita Shukla Department of Obstetrics and Gynecology, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20230534

Keywords:

PROM, Preterm, IVH, MgSO4, APGAR score

Abstract

Background: Globally, prematurity is a leading cause of death in children under the age of five years and in almost all countries with reliable data, preterm birth rates are increasing. This study was conducted to compare the perinatal outcome of preterm deliveries between women receiving MgSO4 and those who were not received MgSO4.

Methods: This randomization study was conducted in department of obstetrics and gynaecology, GSVM Medical College, Kanpur, Uttar Pradesh, India, over a period of one year. After informed consent and ethical clearance from institutional ethics committee, Kanpur, total 100 pregnant women were recruited for this study and were divided into two group of 50 women each. Women in group I were subjected for MgSO4 therapy. Fetal conditions were monitored. These patients were followed up for the next 6 months for outcome.

Results: Overall maternal age ranged from 21 to 32 years. Majority of cases in both the groups were from rural areas and belonged to lower socio-economic status. Majority of women in both the groups were multigravida (68.75%) and (60%) respectively. In both groups, most common risk factors were severe anemia followed by preeclampsia. APGAR score was better in women who received MgSO4, but the difference was found to be statistically significant only for 5 minutes. Although IVH and periventricular leukomalacia rate was higher in group I as compared to that in group II. Although proportion of alive neonates was higher in group I as compared to that in group II yet there was no significant difference between two groups (p=0.961). Incidence of respiratory distress, followed by perinatal asphyxia were most common in both the groups but was not found to be significant statistically (p>0.05).

Conclusions: Proportion of those with Apgar score <7 at 1 minute, 5 minutes and 10 minutes was higher in group II as compared to group I but the difference was significant statistically only at 5 minutes evaluation.

References

World Health Organisation. Preterm Birth. Fact Sheet, November, 2017. Available from: http:/www.who.int/mediacentre/factsheets/fs363/en/. Accessed on 1 December 2018.

Lawn JE, Cousens S, Zupan J, Team LNSS. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365(9462):891-900.

Kuban KC, Leviton A, Pagano M, Fenton T, Strassfeld R, et al. Maternal toxaemia is associated with reduced incidence of germinal matrix haemorrhage in premature babies. J Child Neurol. 1992;7:70-6.

Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birth weight infants? Pediatrics. 1995;95:263-9.

Conde-Agudelo A, Romero R. Antenatal magnesium sulphate for the prevention of cerebral palsy in preterm infants less than 34 weeks’ gestations: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009;200:595-609.

Rouse DJ, Hirtz DG, Thom EA, Eunice Shriver Kennedy National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Magnesium Sulfate for the protection of Cerebral Palsy. N Engl J Med. 2009;360:190.

Zylinska L, Gulczynska E, Kozaczuk A. Changes in erythrocyte glutathione and plasma membrane calcium pump in preterm newborns treated antenatally with MgSO4. Neonatology. 2008;94:272-8.

Nguyen TM, Crowther CA, Wilkinson D, Bain E. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database Syst Rev. 2013;(2):CD009395.

Rauf M, Sevil E, Ebru C, Yavuz S, Cemil C. Antenatal magnesium sulfate use for fetal neuroprotection: eperience from a tertiary care hospital in Turkey. Biomed Res. 2017;289(4):1749-54.

Singh U, Singh N, Seth S. A prospective analysis of etiology and outcome of preterm labour. J Obstet Gynecol India. 2007;57(1):48-52.

Lipi LB, Begum N, Alam UK, Jahan R, Rahman MM, Rumana R. Study on role of magnesium sulphate as a tocolytic agent in preventing preterm labour. J Dhaka Med Coll. 2013;179-184.

Shah S, Yadav L. Preterm birth in rural and urban areas of Hisar, Haryana. Int J Human Soc Sci. 2015;4(4):83-90.

McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2003;1(2):CD000262.

Floyd RC, McLaughlin BN, Martin RW, Roberts WE, Wiser WL, Morrison JC. Comparison of magnesium and nifedipin for primary tocolysis and idiopathic preterm labour. Am J Obstet Gynecol. 1992;166;446.

Zeng X, Xue Y, Tian Q, Sun R, An R. Effects and safety of magnesium sulfate on neuroprotection: a meta analysis based on PRISMA Guidelines. Medicine. 2016;95(1):e2451.

Downloads

Published

2023-02-27

Issue

Section

Original Research Articles